Malondialdehyde-modified low-density lipoprotein is a predictor of cardiac events in patients with stable angina on lipid-lowering therapy after percutaneous coronary intervention using drug-eluting stent

Ito, Tetsuhide; Fujita, Hiroshi; Tani, Tohru; Ohte, Nobuyuki

doi:10.1016/j.atherosclerosis.2015.01.026

Cited by 27 publications

(20 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MDALDL is useful for prognostic prediction of the incidence of CAD and the recurrence of stenosis after percutaneous coronary intervention (PCI) in diabetic patients with a history of CAD 236 ) . In patients with stable angina who were receiving lipid-lowering treatment, the risk for cardiovascular events after treatment using a drug-eluting stent has been shown to increase by 1.14 times with every 10 U/L elevation in MDALDL levels 237 ) .…”

Section: Comprehensive Risk Assessmentmentioning

confidence: 99%

Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017

Kinoshita

Yokote

Arai

et al. 2018

J Atheroscler Thromb

620

569

View full text Add to dashboard Cite

Section: Comprehensive Risk Assessmentmentioning

confidence: 99%

Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017

Kinoshita

Yokote

Arai

et al. 2018

J Atheroscler Thromb

620

569

View full text Add to dashboard Cite

“…These α‐helices promote high affinity binding of lipids – especially oxidized lipids – to the 4F peptide sequence . Since oxidative modification of LDL has been shown to correlate with atherosclerotic severity, high‐affinity binding to oxidized lipids could offer a valuable targeting strategy . Hence, we developed the ApoA1 PA as a platform to use oxidized‐lipid binding to selectively target atherosclerotic plaques.…”

mentioning

confidence: 67%

Peptide Amphiphile Nanostructures for Targeting of Atherosclerotic Plaque and Drug Delivery

Mansukhani

Peters

et al. 2018

Adv. Biosys.

View full text Add to dashboard Cite

Co-assembled peptide amphiphile nanofibers designed to target atherosclerotic plaque and enhance cholesterol efflux are shown to encapsulate and deliver a liver X receptor agonist to increase efflux from murine macrophages in vitro. Fluorescence microscopy reveals that the nanofibers, which display an apolipoprotein-mimetic peptide, localize at plaque sites in LDL receptor knockout mice with or without the encapsulated molecule, while nanofibers displaying a scrambled, non-targeting peptide sequence do not demonstrate comparable binding. These results show that nanofibers functionalized with apolipoprotein-mimetic peptides may be effective vehicles for intravascular targeted drug delivery to treat atherosclerosis.

show abstract

“…after implantation of drug-eluting stents, 36) and MDA-LDL might have an effect on the clinical course in chronic stage VSA patients. Serum MDA-LDL as the target of medical treatment: MDA-LDL may be important to medical treatment after making the diagnosis of VSA.…”

Section: Discussionmentioning

confidence: 99%

Malondialdehyde-Modified Low Density Lipoprotein as Oxidative-Stress Marker in Vasospastic Angina Patients

et al. 2017

View full text Add to dashboard Cite

SummaryVasospastic angina (VSA) is caused by endothelial dysfunction and hypercontraction of vascular smooth muscle cells. Although oxidative-stress can induce endothelial dysfunction, the relationship of VSA and the oxidative-stress marker malondialdehyde-modified low density lipoprotein (MDA-LDL) remains unclear. Purpose: Serum MDA-LDL was evaluated in candidate VSA patients.The subjects were 84 patients admitted to our hospital because of chest pain at rest. We stratified the patients into 3 groups; definite VSA, suspected VSA, and unlikely VSA according to a Japanese Circulation Society (JCS) guideline. The patients classified as definite VSA or suspected VSA were considered as "clinical VSA".Forty cases were classified as definite VSA, 35 as suspected VSA, and 9 as unlikely VSA. Thus, clinical VSA was the diagnosis in 75 cases. The patient characteristics showed that the average age of the patients was 60.2 years old (men, 61%). The serum MDA-LDL level of the clinical VSA group (126.3 ± 38.0 U/L) was significantly higher than the unlikely VSA group (98.7 ± 31.1 U/L). Serum MDA-LDL was positively correlated with total cholesterol (T-Chol), lowdensity lipoprotein cholesterol (LDL-C), triglycerides, and fasting blood glucose. Multivariate analysis showed that serum MDA-LDL was the most predictive marker for making a diagnosis of clinical VSA (Odds ratio 1.064, 95% confidence interval 1.014-1.145, P = 0.008). In a population with positive or borderline ECG change, the positive rate in the acetylcholine provocation test was significantly higher in the MDA-LDL higher group compared to the MDA-LDL lower group (81% versus 37%, P = 0.032).: Serum MDA-LDL might be a useful biomarker of VSA and have additional value for the diagnosis of clinical VSA. (Int Heart J 2017; 58: 335-343)

show abstract

Malondialdehyde-modified low-density lipoprotein is a predictor of cardiac events in patients with stable angina on lipid-lowering therapy after percutaneous coronary intervention using drug-eluting stent

Cited by 27 publications

References 33 publications

Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017

Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017

Peptide Amphiphile Nanostructures for Targeting of Atherosclerotic Plaque and Drug Delivery

Malondialdehyde-Modified Low Density Lipoprotein as Oxidative-Stress Marker in Vasospastic Angina Patients

Contact Info

Product

Resources

About